14 results on '"Bannwarth, Sylvie"'
Search Results
2. E-Health & Innovation to Overcome Barriers in Neuromuscular Diseases. Report from the 1st eNMD Congress: Nice, France, March 22-23, 2019
- Author
-
Pini, Jonathan, Siciliano, Gabriele, Lahaut, Pauline, Braun, Serge, Segovia-Kueny, Sandrine, Kole, Anna, Hérnando, Ines, Selb, Julij, Schirinzi, Erika, Duong, Tina, Hogrel, Jean-Yves, Olmedo, José Javier Serrano, Vissing, John, Servais, Laurent, Vincent-Genod, Dominique, Vuillerot, Carole, Bannwarth, Sylvie, Eggenspieler, Damien, Vicart, Savine, Diaz-Manera, Jordi, Lochmüller, Hanns, and Sacconi, Sabrina
- Abstract
By definition, neuromuscular diseases are rare and fluctuating in terms of symptoms; patients are often lately diagnosed, do not have enough information to understand their condition and be proactive in their management. Usually, insufficient resources or services are available, leading to patients’ social burden. From a medical perspective, the rarity of such diseases leads to the unfamiliarity of the medical staff and caregiver and an absence of consensus in disease assessment, treatment, and management. Innovations have to be developed in response to patients’ and physicians’ unmet needs.It is vital to improve several aspects of patients’ quality of life with a better comprehension of their disease, simplify their management and follow-up, help their caregiver, and reduce the social and economic burden for living with a rare debilitating disease. Database construction regrouping patients’ data and symptoms according to specific country registration on data privacy will be critical in establishing a clear consensus on neuromuscular disease treatment.Clinicians also need technological innovations to help them recognize neuromuscular diseases, find the best therapeutic approach based on medical consensus, and tools to follow patients’ states regularly. Diagnosis also has to be improved by implementing automated systems to analyze a considerable amount of data, representing a significant step forward to accelerate the diagnosis and the patients’ follow up. Further, the development of new tools able to precisely measure specific outcomes reliably is of the matter of importance in clinical trials to assess the efficacy of a newly developed compound.In this context, creation of an expert community is essential to communicate and share ideas. To this end, 97 clinicians, healthcare professionals, researchers, and representatives of private companies from 9 different countries met to discuss the new perspective and challenges to develop and implement innovative tools in the field of neuromuscular diseases.
- Published
- 2021
- Full Text
- View/download PDF
3. Clinical phenotype of mitochondrial diabetes due to rare mitochondrial DNA mutations
- Author
-
Decoux-Poullot, Anne-Gaëlle, Bannwarth, Sylvie, Procaccio, Vincent, Lebre, Anne-Sophie, Jardel, Claude, Vialettes, Bernard, Paquis-Flucklinger, Véronique, and Chevalier, Nicolas
- Abstract
While the most frequent mutation responsible for mitochondrial diabetes is the point mutation m.3243 A>G of mitochondrial DNA (mtDNA), few data are available about the role of rare mtDNA mutations in the pathophysiology of diabetes. The main objective of our study was to describe the phenotypic characteristics of patients suffering from diabetes linked to rare mtDNA mutations.
- Published
- 2020
- Full Text
- View/download PDF
4. NDUFS6related Leigh syndrome: a case report and review of the literature
- Author
-
Rouzier, Cécile, Chaussenot, Annabelle, Fragaki, Konstantina, Serre, Valérie, Ait-El-Mkadem, Samira, Richelme, Christian, Paquis-Flucklinger, Véronique, and Bannwarth, Sylvie
- Abstract
The genetic causes of Leigh syndrome are heterogeneous, with a poor genotype–phenotype correlation. To date, more than 50 nuclear genes cause nuclear gene-encoded Leigh syndrome. NDUFS6encodes a 13 kiloDaltons subunit, which is part of the peripheral arm of complex I and is localized in the iron-sulfur fraction. Only a few patients were reported with proven NDUFS6pathogenic variants and all presented with severe neonatal lactic acidemia and complex I deficiency, leading to death in the first days of life. Here, we present a patient harboring two NDUFS6variants with a phenotype compatible with Leigh syndrome. Although most of previous reports suggested that NDUFS6pathogenic variants invariably lead to early neonatal death, this report shows that the clinical spectrum could be larger. We found a severe decrease of NDUFS6 protein level in patient’s fibroblasts associated with a complex I assembly defect in patient’s muscle and fibroblasts. These data confirm the importance of NDUFS6 and the Zn-finger domain for a correct assembly of complex I.
- Published
- 2019
- Full Text
- View/download PDF
5. Coenzyme Q10defects may be associated with a deficiency of Q10-independent mitochondrial respiratory chain complexes
- Author
-
Fragaki, Konstantina, Chaussenot, Annabelle, Benoist, Jean-François, Ait-El-Mkadem, Samira, Bannwarth, Sylvie, Rouzier, Cécile, Cochaud, Charlotte, and Paquis-Flucklinger, Véronique
- Abstract
Coenzyme Q10(CoQ10or ubiquinone) deficiency can be due either to mutations in genes involved in CoQ10biosynthesis pathway, or to mutations in genes unrelated to CoQ10biosynthesis. CoQ10defect is the only oxidative phosphorylation disorder that can be clinically improved after oral CoQ10supplementation. Thus, early diagnosis, first evoked by mitochondrial respiratory chain (MRC) spectrophotometric analysis, then confirmed by direct measurement of CoQ10levels, is of critical importance to prevent irreversible damage in organs such as the kidney and the central nervous system. It is widely reported that CoQ10deficient patients present decreased quinone-dependent activities (segments I + III or G3P + III and II + III) while MRC activities of complexes I, II, III, IV and V are normal. We previously suggested that CoQ10defect may be associated with a deficiency of CoQ10-independent MRC complexes. The aim of this study was to verify this hypothesis in order to improve the diagnosis of this disease. To determine whether CoQ10defect could be associated with MRC deficiency, we quantified CoQ10by LC-MSMS in a cohort of 18 patients presenting CoQ10-dependent deficiency associated with MRC defect. We found decreased levels of CoQ10in eight patients out of 18 (45 %), thus confirming CoQ10disease. Our study shows that CoQ10defect can be associated with MRC deficiency. This could be of major importance in clinical practice for the diagnosis of a disease that can be improved by CoQ10supplementation.
- Published
- 2016
- Full Text
- View/download PDF
6. Rapid identification of unknown heteroplasmic mutations across the entire human mitochondrial genome with mismatch-specific Surveyor Nuclease
- Author
-
Bannwarth, Sylvie, Procaccio, Vincent, and Paquis-Flucklinger, Veronique
- Abstract
Mitochondrial DNA (mtDNA) mutations are responsible for mitochondrial diseases in numerous patients. But, until now, no rapid method was available for the identification of unknown deleterious point mutations. Here, we describe a new strategy for the rapid identification of heteroplasmic mtDNA mutations using mismatch-specific Surveyor Nuclease. This protocol involves the following three steps: (i) PCR amplification of the entire human mitochondrial genome in 17 overlapping fragments; (ii) localization of mtDNA mismatch(es) after digestion of the 17 amplicons by Surveyor Nuclease; and (iii) identification of the mutation by sequencing the region containing the mismatch. This Surveyor Nuclease-based strategy allows a systematic screening of the entire mtDNA to identify a mutation within 2 days. It represents an important diagnostic approach for mitochondrial diseases that can be routinely used in molecular diagnostic laboratories.
- Published
- 2006
- Full Text
- View/download PDF
7. HIV-1 TAR RNA: The Target of Molecular Interactions Between the Virus and its Host
- Author
-
Bannwarth, Sylvie and Gatignol, Anne
- Abstract
HIV-1 TAR RNA is the binding site of the viral protein Tat, the trans-activator of the HIV-1 LTR. It is present at the 5 end of all HIV-1 spliced and unspliced mRNAs in the nucleus as well as in the cytoplasm. It has a highly folded stem-bulge-loop structure, which also binds cellular proteins to form ribonucleoprotein complexes. The Tat-Cyclin T1-CDK9 complex is the main component in the trans-activation of HIV-1 and its affinity for TAR is regulated through Tat acetylation by histone acetyl transferases. Recent studies show that this complex is able to recruit other cellular partners to mediate efficient transcriptional elongation. TRBP, PKR and La bind directly to the TAR RNA structure and influence translation of HIV-1 in either positive or negative manners. Some mutations in TAR RNA severely impair HIV-1 trans-activation, translation and viral production, showing its functional importance. The overexpression or suppression of several TAR RNAbinding proteins has a strong impact on viral replication pointing out their major role in the viral life cycle. TAR RNA has been the target of drug development to inhibit viral replication. Recent data using small molecules or RNA-based technologies show that acting on the TAR RNA or on its viral and cellular binding factors effectively decreases virion production.
- Published
- 2005
8. Astrocyte Infection by HIV-1: Mechanisms of Restricted Virus Replication, and Role in the Pathogenesis of HIV-1-Associated Dementia
- Author
-
Gorry, Paul R., Ong, Chi, Thorpe, Janine, Bannwarth, Sylvie, Thompson, Katherine A., Gatignol, Anne, Wesselingh, Steven L., and Purcell, Damian F.J.
- Abstract
Astrocytes are the most numerous cell type in the brain, and their physiological roles are essential for normal brain function. Studies of post-mortem brain tissue samples from individuals with AIDS have revealed that a small proportion of astrocytes are infected by HIV-1 which is linked to the development of HIVassociated dementia (HIVD), a frequent clinical manifestation of HIV-1 disease affecting up to 20% of infected adults. However, astrocyte infection by HIV-1 in vivo is generally non-productive, and can only be readily detected by sensitive techniques that detect HIV-1 RNA or proviral DNA. Similarly, primary astrocyte cultures and astrocytic cell lines can be permissive to infection by HIV-1 strains, but are refractory to efficient HIV-1 expression. In efforts to delineate the molecular mechanisms underlying the "restricted" infection, several studies have demonstrated that efficient HIV-1 replication is blocked in astrocytes at different steps of the virus life cycle, including virus entry, reverse transcription, nucleocytoplasmic HIV-1 RNA transport, translation of viral RNA, and maturation of progeny virions. However, the relative importance of each of these possible replication blocks in restricting HIV-1 replication in astrocytes is unclear. Moreover, how restricted astrocyte infection contributes to the development of HIVD is unknown. This review surveys the current in vitro models of restricted HIV-1 replication in astrocytes, and provides an analysis of the available evidence supporting a role for astrocyte infection in the pathogenesis of HIVD. A greater understanding of the fate of HIV-1 in astrocytes may assist in the identification of viral reservoirs in the central nervous system, novel therapies for the treatment of HIVD, and also novel strategies to suppress HIV-1 replication in CD4+ cells of the immune system.
- Published
- 2003
9. Additive Activity between the Trans-Activation Response RNA-Binding Protein, TRBP2, and Cyclin T1 on HIV Type 1 Expression and Viral Production in Murine Cells
- Author
-
Battisti, Pier-Luigi, Daher, Aïcha, Bannwarth, Sylvie, Voortman, Johannes, Peden, Keith W.C., Hiscott, John, Mouland, Andrew J., Benarous, Richard, and Gatignol, Anne
- Abstract
Tat-mediated trans-activation of the HIV-1 long terminal repeat (LTR) occurs through the phosphorylation of the carboxy-terminal domain of the RNA polymerase II. The kinase complex, pTEFb, composed of cyclin T1 (CycT1) and CDK9, mediates this process. The trans-activation response (TAR) RNA-binding protein 2 (TRBP2) increases HIV-1 LTR expression through TAR and protein kinase R (PKR) binding, but not through interactions with the Tat-CycT1-CDK9 complex. TRBP2 and the Tat-CycT1-CDK9 complex have overlapping binding sites on TAR RNA. TRBP2 and CycT1 increased Tat trans-activation in NIH 3T3 cells with additive effects. Upon transfection of HIV-1 pLAI, pNL4-3, pMAL, and pAD molecular clones, reverse transcriptase (RT) activity and p24 concentration were decreased 200- to 900-fold in NIH 3T3 cells compared with HeLa cells in both cells and supernatants. In murine cells, cotransfection of the HIV clones with CycT1 or TRBP2 increased modestly the expression of RT activity in cell extracts. The analysis of Gag expression in murine cells transfected with CycT1 compared with human cells showed a 20-fold decrease in expression and a strong processing defect. The expression of both CycT1 and TRBP2 had a more than additive activity on RT function in cell extracts and on viral particle production in supernatant of murine cells. These results suggest an activity of CycT1 and TRBP2 at different steps in HIV-1 expression and indicate the requirement for another posttranscriptional factor in murine cells for full HIV replication.
- Published
- 2003
- Full Text
- View/download PDF
10. Organization of the Human tarbp2Gene Reveals Two Promoters That Are Repressed in an Astrocytic Cell Line*
- Author
-
Bannwarth, Sylvie, Talakoub, Lily, Letourneur, Franck, Duarte, Mariela, Purcell, Damian F., Hiscott, John, and Gatignol, Anne
- Abstract
TRBP1 and TRBP2 are isoforms of a double-stranded RNA-binding protein that differ in their N-terminal end and were each identified by binding to human immunodeficiency virus type 1 (HIV-1) trans-activation-responsive RNA. TRBP1 and TRBP2 also bind and modulate the function of the double-stranded RNA-activated protein kinase, protein kinase R. Both proteins increase long terminal repeat expression in human and murine cells, and their gene has been mapped to human chromosome 12. We have isolated and characterized the complete tarbp2gene (5493 bp) coding for the two TRBP proteins. Two adjacent promoters initiate transcription of alternative first exons for TRBP1 and TRBP2 mRNAs that are spliced onto common downstream exons. TRBP2 transcription and translation start sites are localized within the first intron of TRBP1. TRBP promoters are TATA-less but have CCAAT boxes, a CpG island, and several potential binding sites for transcriptional factors. Promoter deletion analysis identified two regions from position −1397 to −330 for TRBP1 and from position −330 to +38 for TRBP2 that are important for promoter function. TRBP2 promoter activity was expressed at a higher level compared with TRBP1 promoter. In addition, a specific down-regulation of TRBP1 and TRBP2 promoter activity was identified in human astrocytic cell line U251MG compared with HeLa cells. This minimal TRBP promoter activity may account for minimal HIV-1 replication in astrocytes.
- Published
- 2001
- Full Text
- View/download PDF
11. Two Dimerization Domains in the Trans-activation Response RNA-binding Protein (TRBP) Individually Reverse the Protein Kinase R Inhibition of HIV-1 Long Terminal Repeat Expression*
- Author
-
Daher, Aı̈cha, Longuet, Michèle, Dorin, Dominique, Bois, Florence, Segeral, Emmanuel, Bannwarth, Sylvie, Battisti, Pier-Luigi, Purcell, Damian F., Benarous, Richard, Vaquero, Catherine, Meurs, Eliane F., and Gatignol, Anne
- Abstract
Trans-activation response (TAR) RNA-binding protein (TRBP) is a cellular protein that binds to the human immunodeficiency virus-1 (HIV-1) TAR element RNA. It has two double-stranded RNA binding domains (dsRBDs), but only one is functional for TAR binding. TRBP interacts with the interferon-induced protein kinase R (PKR) and inhibits its activity. We used the yeast two-hybrid assay to map the interaction sites between the two proteins. We show that TRBP and PKR-N (178 first amino acids of PKR) interact with PKR wild type and inhibit the PKR-induced yeast growth defect in this assay. We characterized two independent PKR-binding sites in TRBP. These sites are located in each dsRBD in TRBP, indicating that PKR-TRBP interaction does not require the RNA binding activity present only in dsRBD2. TRBP and its fragments that interact with PKR reverse the PKR-induced suppression of HIV-1 long terminal repeat expression. In addition, TRBP activates the HIV-1 long terminal repeat expression to a larger extent than the addition of each domain. These data suggest that TRBP activates gene expression in PKR-dependent and PKR-independent manners.
- Published
- 2001
- Full Text
- View/download PDF
12. Molecular Cloning of a New Secreted Sulfated Mucin-like Protein With a C-type Lectin Domain That Is Expressed in Lymphoblastic Cells*
- Author
-
Bannwarth, Sylvie, Giordanengo, Valérie, Lesimple, Josette, and Lefebvre, Jean-Claude
- Abstract
We have previously demonstrated hyposialylation of the two major CD45 and leukosialin (CD43) molecules at the surface of latently human immunodeficiency virus type 1-infected CEM T cells (CEMLAI/NP), (Lefebvre, J. C., Giordanengo, V., Doglio, A., Cagnon, L., Breittmayer, J. P., Peyron, J. F., and Lesimple, J. (1994) Virology199, 265–274; Lefebvre, J. C., Giordanengo, V., Limouse, M., Doglio, A., Cucchiarini, M., Monpoux, F., Mariani, R., and Peyron, J. F. (1994) J. Exp. Med.180, 1609–1617). Searching to clarify mechanism(s) of hyposialylation, we observed two sulfated secreted glycoproteins (molecular mass ∼47 and ∼40 kDa) (P47 and P40), which were differentially sulfated and/or differentially secreted in the culture supernatants of CEMLAI/NP cells when compared with parental CEM cells. A hybridoma clone (7H1) resulting from the fusion between CEMLAI/NP and human embryonic fibroblasts MRC5 cells produced very large amounts of P47 that was purified using Jacalin lectin (specific for O-glycans) and microsequenced. Cloning of P47 was achieved using a CEMLAI/NP cDNA library screened with a degenerate oligonucleotide probe based on its NH2-terminal amino acid sequence. A single open reading frame encoding a protein of 323 amino acids was deduced from the longest isolated recombinant (1.4 kilobase). P47 is a secreted sulfated protein. It carries an NH2-terminal RGD (Arg-Gly-Asp) triplet, a striking α-helical leucine zipper composed of six heptads, and a C-terminal C-type lectin domain. The NH2-terminal portion is rich in glutamic acids with a predicted pI of 3.9. In addition, a hinge region with numerous condensed potential sites forO-glycan side chains, which are also the most likely sulfation sites, is located between the RGD and leucine zipper domains. Transcripts were detected in lymphoid tissues (notably bone marrow) and abundantly in T and B lymphoblastoid but very faintly in monocytoid cell lines.
- Published
- 1998
- Full Text
- View/download PDF
13. Preuve d’une origine mitochondriale pour les phénotypes SLA/DFT à travers l’identification d’un nouveau gène CHCHD10
- Author
-
Chaussenot, Annabelle, Le Ber, Isabelle, Bannwarth, Sylvie, Ait El Kadem, Samira, Verschueren, Annie, Pouget, Jean, and Paquis-Flucklinger, Véronique
- Abstract
Le spectre clinique associé à l’instabilité de l’ADN mitochondrial (ADNmt) est large, mais l’atteinte du motoneurone type SLA (sclérose latérale amyotrophique) et la démence frontotemporale (DFT) sont extrêmement rares.
- Published
- 2015
- Full Text
- View/download PDF
14. Cloning, Mapping, and Genomic Organization of the LSLCL Gene, Encoding a New Lymphocytic Secreted Mucin-like Protein with a C-Type Lectin Domain: A New Model of Exon Shuffling
- Author
-
Bannwarth, Sylvie, Giordanengo, Valérie, Grosgeorge, Josiane, Turc-Carel, Claude, and Lefebvre, Jean-Claude
- Published
- 1999
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.